BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fadeucravacitinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Fadeucravacitinib\, from ClinicalTrials.g
 ov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07440537-1808@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Fadeucravacitinib: Phase 2 readout est. (NCT07440537)
DESCRIPTION:Fadeucravacitinib\, phase 2.\nStudy: Evaluate the Efficacy and 
 Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Dou
 ble-blind Study\nEstimated primary completion: March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/fadeucravacitinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07440537
URL:https://assetmemo.bio/drug/fadeucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07727486-1808@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Fadeucravacitinib: Phase 2 readout est. (NCT07727486)
DESCRIPTION:Fadeucravacitinib\, phase 2.\nStudy: A Study to Evaluate the Ef
 ficacy and Safety of ICP-488 in Participants With Primary Sjögren's Syndr
 ome\nEstimated primary completion: December 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/fadeucravacitinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07727486
URL:https://assetmemo.bio/drug/fadeucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
